Tezepelumab in Mexican Patients with Severe Asthma TH2 predominant: A series of cases

Background: Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) has demonstrated efficacy for severe asthma patients in clinical trials and real-world evidence in limited data. We describe the characteristics of five patients in a pulmonary clinic in Puebla, Mexico initiating Tezepelumab in a real-world setting.
Methods: We presented 5 cases from a series of cases in a center of pulmonary unit in Puebla City, Mexico to evaluate the real-world effectiveness of Tezepelumab in patients with severe asthma. Eligible patients were adults with a confirmed diagnosis of severe asthma treated with Tezepelumab. Data with symptoms, pulmonary function and corticosteroid use were collected and analyzed at baseline, six months and 1 year follow up.
Results: A total of 5 patients were included. The average age was 52 years. 100% of the patients had more than 2 exacerbations previous year. 40% had prior biologic therapy and 60% had eosinophil count <300 cells/μL. At follow up, 100% reduction in annual exacerbations. There were significant improvements in forced expiratory volume in one second (FEV1) and Fraction Exhaled of nitric oxide (FENO). All the patients discontinued oral corticosteroids and 80% continued with triple therapy.
Conclusion: A series of cases presented with Tezepelumab from 6 months to 1 year follow up were improved asthma control, reductions in exacerbations, discontinued corticosteroid use and very low symptoms. Tezepelumab demonstrated that is a safety biologic treatment and improvement symptoms.

Keywords:Severe asthma; Biologic therapy; Tezepelumab; Cases